Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Clin Cancer Res. 2008 Nov 15;14(22):7413–7422. doi: 10.1158/1078-0432.CCR-08-0239

Fig. 3.

Fig. 3

Quantitative in vivo imaging of NIR800-EGF uptake reflects the relative EGFR immunoreactivity in colorectal cancer xenografts. A, representative in vivo fluorescence images of SW620 (EGFR-negative), HCT-116 (EGFR-moderate), and DiFi (EGFR-high) tumor-bearing mice 24 h post-administration of NIR800-EGF. T, tumor; K, kidney. B, relative in vivo uptake of NIR800-EGF in SW620, HCT-116, and DiFi tumors. C, total EGFR immunoreactivity in tumor specimens from SW620, HCT-116, and DiFi xenografts shown in A and B.